IMPRiND

Inhibiting misfolded protein propagation in neurodegenerative diseases
Inhibiting misfolded protein propagation in neurodegenerative diseases

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 7
Grant agreement number
116060

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
4 685 000
EFPIA in kind
6 365 900
Other
312 500
Total Cost
11 363 400

Summary

Alzheimer’s and Parkinson’s diseases are neurodegenerative disorders that affect 45 million and 10 million people worldwide respectively. There is currently no cure for these diseases, which place an immense burden on carers, many of whom are family members. Both diseases are characterised by the progressive loss of brain cells. Recent evidence suggests that this loss may be due to the release and uptake by brain cells of specific aggregated proteins (misfolded proteins which clump together leading to a progressive spreading of the degeneration). If these processes could be blocked, disease progression could be halted. However, the forces driving these processes are currently poorly understood. Working to change that is the IMPRiND project, which aims to understand how these aggregated proteins are handled once inside brain cells and how they are moved from cell to cell. To do this, the project team will work collaboratively to develop standardised tools and tests to establish disease-relevant mechanisms that could be targeted by drugs in the future.

Participants Show participants on map

EFPIA companies
  • AbbVie Ltd, Maidenhead, United Kingdom
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • H. Lundbeck As, Valby, Denmark
  • Institut De Recherches Servier, Suresnes, France
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Aarhus Universitet, Aarhus C, Denmark
  • Centre National De La Recherche Scientifique Cnrs, Paris, France
  • Deutsches Zentrum Fur Neurodegenerative Erkrankungen Ev, Bonn, Germany
  • Idryma Iatroviologikon Ereunon Akademias Athinon, Athens, Greece
  • United Kingdom Research And Innovation
  • Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts, Goettingen, Germany
  • Universite De Bordeaux, Bordeaux, France
  • University Of Dundee, Dundee, United Kingdom
  • University of Cambridge, Cambridge, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • Vib, Zwijnaarde - Gent, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Sciprom SARL, St-Sulpice, Switzerland

CONTACT

Project leader
Kenneth Thirstrup
H. Lundbeck A/S
KETH[at]lundbeck.com
Project coordinator
Gill WELLS
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
ecresearch[at]admin.ox.ac.uk
Project office and general enquires
Dr. Kirsten Leufgen
SCIPROM
+41 216940412